Effective inhibition of bone morphogenetic protein function by highly specific llama-derived antibodies

Molecular Cancer Therapeutics

Volumn 14, Issue 11, 2015, Pages 2527-2540

  Calpe, Silvia ^a   Wagner, Koen ^a   El Khattabi, Mohamed ^b   Rutten, Lucy ^b   Zimberlin, Cheryl ^c   Dolk, Edward ^b   Verrips, C Theo ^b   Medema, Jan Paul ^c   Spits, Hergen ^a   Krishnadath, Kausilia K ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b QVQ BV   (Netherlands)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BONE MORPHOGENETIC PROTEIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 5; BONE MORPHOGENETIC PROTEIN 6; EPITOPE; LLAMA DERIVED ANTIBODY; UNCLASSIFIED DRUG; BMP2 PROTEIN, HUMAN; BMP4 PROTEIN, HUMAN; PROTEIN BINDING;

ANIMAL CELL; ANTIBODY SPECIFICITY; ARTICLE; BINDING AFFINITY; CELL ACTIVATION; CELL CULTURE; CHEMOSENSITIVITY; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOLECULAR DOCKING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; STEM CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; ANTIBODY AFFINITY; CELL LINE; CHEMICAL STRUCTURE; CHEMISTRY; HT 29 CELL LINE; IMMUNOLOGY; METABOLISM; NEOPLASMS; NEW WORLD CAMELID; PROTEIN TERTIARY STRUCTURE; WESTERN BLOTTING;

ANIMALS; ANTIBODIES; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEINS; CAMELIDS, NEW WORLD; CELL LINE; HT29 CELLS; HUMANS; MICE; MODELS, MOLECULAR; NEOPLASMS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 84958171627     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0956     Document Type: Article

References (53)

1. Bragdon B, Moseychuk O, Saldanha S, King D, Julian J, Nohe A. Bone morphogenetic proteins: a critical review. Cell Signal 2011;23: 609-20.
2. Miyazono K, Kamiya Y, Morikawa M. Bone morphogenetic protein receptors and signal transduction. J Biochem (Tokyo) 2010;147: 35-51.
3. Mueller TD, Nickel J. Promiscuity and specificity in BMP receptor activation. FEBS Lett 2012;586:1846-59.
4. Ehrlich M, Horbelt D, Marom B, Knaus P, Henis YI. Homomeric and heteromeric complexes among TGF-b and BMP receptors and their roles in signaling. Cell Signal 2011;23:1424-32.
5. TenDijke P, Korchynskyi O, ValdimarsdottirG,Goumans M-J. Controlling cell fate by bone morphogenetic protein receptors. Mol Cell Endocrinol 2003;211:105-13.
6. Miyazono K, Maeda S, Imamura T. BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev 2005;16:251-63.
7. Ehata S, Yokoyama Y, Takahashi K, Miyazono K. Bi-directional roles of bone morphogenetic proteins in cancer: another molecular Jekyll and Hyde? Pathol Int 2013;63:287-96.
8. Singh A, Morris RJ. The Yin and Yang of bone morphogenetic proteins in cancer. Cytokine Growth Factor Rev 2010;21:299-313.
9. Kallioniemi A. Bone morphogenetic protein 4 - a fascinating regulator of cancer cell behavior. Cancer Genet 2012;205:267-77.
10. Piccirillo SGM, Reynolds BA, Zanetti N, Lamorte G, Binda E, Broggi G, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature 2006;444:761-5.
11. Holien T, Sundan A. The role of bone morphogenetic proteins in myeloma cell survival. Cytokine Growth Factor Rev 2014;25:343-50.
12. Ampuja M, Jokimäki R, Juuti-Uusitalo K, Rodriguez-Martinez A, Alarmo E-L, Kallioniemi A. BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. BMC Cancer 2013;13:429.
13. Thériault BL, Shepherd TG, Mujoomdar ML, Nachtigal MW. BMP4 induces EMT and Rho GTPase activation in human ovarian cancer cells. Carcinogenesis 2007;28:1153-62.
14. Hao J, Lee R, Chang A, Fan J, Labib C, Parsa C, et al. DMH1, a small molecule inhibitor of BMP type i receptors, suppresses growth and invasion of lung cancer. PLoS One 2014;9:e90748.
15. Lee Y-C, Cheng C-J, Bilen MA, Lu J-F, Satcher RL, Yu-Lee L-Y, et al. BMP4 promotes prostate tumor growth in bone through osteogenesis. Cancer Res 2011;71:5194-203.
16. Virtanen S, Alarmo E-L, Sandström S, Ampuja M, Kallioniemi A. Bone morphogenetic protein-4 and-5 in pancreatic cancer - Novel bidirectional players. Exp Cell Res 2011;317:2136-46.
17. Deng H, Makizumi R, Ravikumar TS, Dong H, Yang W, Yang W-L. Bone morphogenetic protein-4 is overexpressed in colonic adenocarcinomas and promotes migration and invasion of HCT116 cells. Exp Cell Res 2007;313:1033-44.
18. Ivanova T, Zouridis H, Wu Y, Cheng LL, Tan IB, Gopalakrishnan V, et al. Integrated epigenomics identifies BMP4 as a modulator of cisplatin sensitivity in gastric cancer. Gut 2013;62:22-33.
19. Hong CC, Yu PB. Applications of small molecule BMP inhibitors in physiology and disease. Cytokine Growth Factor Rev 2009;20: 409-18.
20. Owens P, Pickup MW, Novitskiy SV, Giltnane JM, Gorska AE, Hopkins CR, et al. Inhibition of BMP signaling suppresses metastasis in mammary cancer. Oncogene 2015;34:2437-49.
21. Hao J, Ho JN, Lewis JA, Karim KA, Daniels RN, Gentry PR, et al. In vivo structure-activity relationship study of dorsomorphin analogues identifies selective VEGF and BMP inhibitors. ACS Chem Biol 2010;5:245-53.
22. Engers DW, Frist AY, Lindsley CW, Hong CC, Hopkins CR. Synthesis and structure-activity relationships of a novel and selective bone morphogenetic protein receptor (BMP) inhibitor derived from the pyrazolo[1.5-a]pyrimidine scaffold of Dorsomorphin: the discovery of ML347 as an ALK2 versus ALK3 selective MLPCN probe. Bioorg Med Chem Lett 2013;23:3248-52.
23. Sanvitale CE, Kerr G, Chaikuad A, Ramel M-C, Mohedas AH, Reichert S, et al. A new class of small molecule inhibitor of BMP signaling. PLoS ONE 2013;8:e62721.
24. Vogt J, Traynor R, Sapkota GP. The specificities of small molecule inhibitors of the TGFb and BMP pathways. Cell Signal 2011;23:1831-42.
25. Gao H, Chakraborty G, Lee-Lim AP, Mo Q, Decker M, Vonica A, et al. The BMP inhibitor Coco reactivates breast cancer cells at lung metastatic sites. Cell 2012;150:764-79.
26. Whissell G, Montagni E, Martinelli P, Hernando-Momblona X, Sevillano M, Jung P, et al. The transcription factor GATA6 enables self-renewal of colon adenoma stem cells by repressing BMPgene expression. Nat Cell Biol 2014;16:695-707.
27. Deffar K, Shi H, Li L, Wang X, Zhu X. Nanobodies - the new concept in antibody engineering. Afr J Biotechnol [Internet]. 2009 [cited 2014 Apr 15]; 8. Available from: http://www.ajol.info/index.php/ajb/article/view/ 60807.
28. Harada H, Nakagawa H, Oyama K, Takaoka M, Andl CD, Jacobmeier B, et al. Telomerase induces immortalization of human esophageal keratinocytes without p16INK4a inactivation. Mol Cancer Res MCR 2003;1: 729-38.
29. Mari L, Milano F, Parikh K, Straub D, Everts V, Hoeben KK, et al. A pSMAD/ CDX2 complex is essential for the intestinalization of epithelial metaplasia. Cell Rep 2014;7:1197-210.
30. Zilberberg L, Dijke P ten, Sakai LY, Rifkin DB. Arapid and sensitive bioassay to measure bone morphogenetic protein activity.BMCCell Biol 2007;8:41.
31. Milano F, van Baal JWPM, Buttar NS, Rygiel AM, de Kort F, DeMars CJ, et al. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 2007;132:2412-21.
32. Lokate AMC, Beusink JB, Besselink GAJ, Pruijn GJM, Schasfoort RBM. Biomolecular interaction monitoring of autoantibodies by scanning surface plasmon resonancemicroarray imaging. J AmChem Soc 2007;129: 14013-8.
33. Dominguez C, Boelens R, Bonvin AMJJ. HADDOCK: a protein-protein docking approach based on biochemical or biophysical information. J Am Chem Soc 2003;125:1731-7.
34. Sato T, Vries RG, Snippert HJ, van de WeteringM, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature 2009;459:262-5.
35. Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, Feng X, et al. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLoS One 2012;7:e29941.
36. Keller S, Nickel J, Zhang J-L, Sebald W, Mueller TD. Molecular recognition of BMP-2 and BMP receptor IA. Nat Struct Mol Biol 2004;11:481-8.
37. Kirsch T, Sebald W, Dreyer MK. Crystal structure of the BMP-2-BRIA ectodomain complex. Nat Struct Biol 2000;7:492-6.
38. Allendorph GP, Vale WW, Choe S. Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc Natl Acad Sci U S A 2006;103:7643-8.
39. Greenwald J, Groppe J, Gray P, Wiater E, Kwiatkowski W, Vale W, et al. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol Cell 2003;11:605-17.
40. Kirsch T, Nickel J, Sebald W. BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J 2000;19: 3314-24.
41. Nickel J, Dreyer MK, Kirsch T, Sebald W. The crystal structure of the BMP-2: BMPR-IA complex and the generation of BMP-2 antagonists. J Bone Joint Surg Am 2001;83-A Suppl 1:S7-14.
42. Groppe J, Greenwald J, Wiater E, Rodriguez-Leon J, Economides AN, Kwiatkowski W, et al. Structural basis of BMP signalling inhibition by the cystine knot protein Noggin. Nature 2002;420:636-42.
43. Weber D, Kotzsch A, Nickel J, Harth S, Seher A, Mueller U, et al. A silent H-bond can be mutationally activated for high-affinity interaction of BMP-2 and activin type IIB receptor. BMC Struct Biol 2007;7:6.
44. Voorneveld PW, Kodach LL, Jacobs RJ, van Noesel CJM, Peppelenbosch MP, Korkmaz KS, et al. The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC. Br J Cancer 2015;112:122-30.
45. Muyldermans S.Nanobodies: natural single-domain antibodies. Annu Rev Biochem 2013;82:775-97.
46. Harmsen MM, De Haard HJ. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol 2007;77:13-22.
47. De Meyer T, Muyldermans S, Depicker A. Nanobody-based products as research and diagnostic tools. Trends Biotechnol 2014;32:263-70.
48. Voorneveld PW, Kodach LL, Jacobs RJ, Liv N, Zonnevylle AC, Hoogenboom JP, et al. Loss of SMAD4 alters BMP signaling to promote colorectal cancer cell metastasis via activation of Rho and ROCK. Gastroenterology 2014;147:196-208.
49. Zimmerman LB, De Jesús-Escobar JM, Harland RM. The Spemann organizer signal noggin binds and inactivates bone morphogenetic protein 4. Cell 1996;86:599-606.
50. Lin SJ, Lerch TF, Cook RW, Jardetzky TS, Woodruff TK. The structural basis of TGF-beta, bone morphogenetic protein, and activin ligand binding. Reprod Camb Engl 2006;132:179-90.
51. Desmyter A, Decanniere K, Muyldermans S, Wyns L. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem 2001;276:26285-90.
52. Ruppert R, Hoffmann E, Sebald W. Human bone morphogenetic protein 2 contains a heparin-binding site which modifies its biological activity. Eur J Biochem 1996;237:295-302.
53. Choi YJ, Lee JY, Park JH, Park JB, Suh JS, Choi YS, et al. The identification of a heparin binding domain peptide from bone morphogenetic protein-4 and its role on osteogenesis. Biomaterials 2010;31:7226-38.